tricaprylyl glycerol
Small moleculeexperimental
Clinical trial activity
18 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
3
Phase 3
3
Phase 4
1
Earliest trial started Sep 24, 2010 (NCT01211782)
Timeline
Indications
Approved for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC- Mol. weight
- 470.69 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1406148 ↗
Also known as
- ac-sd-01
- caprylic acid triglyceride
- caprylic acid triglyceride
- caprylic triglyceride
- caprylic triglyceride
- caprylic triglyceride
- caprylidene
- caprylidene
- glycerol tricaprylate
- glycerol tricaprylate
- glycerol trioctanoate
- glycerol trioctanoate
- glyceryl tricaprylate
- glyceryl trioctanoate
- octanoic acid, 1,2,3- propanetriyl ester
- panasate 800
- tricaprilin
- tricaprilin
- tricaprylin
- tricaprylin
- tricaprylin
- tricaprylyl glycerin
- tricaprylyl glycerin
- tricaprylyl glycerol
- tricaprylyl glycerol
- trioctanoin
- trioctanoin
- trioctanoin
- trioctanoylglyceride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05809908 | Phase 3 | Jan 31, 2024 | Cerecin |
| NCT04727970 | Phase 1 | Nov 30, 2021 | Cerecin |
| NCT05028114 | Phase 1 | Aug 31, 2021 | Cerecin |
| NCT04437199 | Phase 2 | Aug 27, 2020 | Cerecin |
| NCT04187547 | Phase 3 | Apr 30, 2020 | Cerecin |
| NCT04268953 | Phase 1 | Feb 28, 2020 | Cerecin |
| NCT03971123 | Phase 1 | Aug 6, 2019 | Cerecin |
| NCT03628352 | Phase 1 | Sep 10, 2018 | Cerecin, Senopsys, LLC |
| NCT03551769 | Phase 1 | Aug 5, 2018 | Cerecin |
| NCT03223389 | N/A | Aug 7, 2017 | University of Copenhagen |
| NCT03063645 | Phase 1 | Mar 11, 2017 | Celerion, Cerecin |
| NCT02833012 | Phase 1 | Jul 1, 2016 | Celerion, Cerecin |
| NCT02747602 | Phase 1 | Apr 1, 2016 | Celerion, Cerecin |
| NCT02602158 | Early Phase 1 (Phase 1) | Oct 1, 2015 | University of Zurich |
| NCT02679222 | N/A | Jun 30, 2015 | University of Sherbrooke |
| NCT01848327 | N/A | Feb 1, 2013 | Cerecin, National Multiple Sclerosis Society, University of Miami |
| NCT01122329 | Phase 4 | Oct 1, 2010 | John Douglas French Foundation, University of California, Los Angeles |
| NCT01211782 | Phase 2/Phase 3 (Phase 3) | Sep 24, 2010 | Cerecin, Meridien Research |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cerecin | For profit | 14 | 13 | 4 | 2010 |
| Celerion | For profit | 3 | 0 | 1 | 2016 |
| John Douglas French Foundation | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Meridien Research | For profit | 1 | 0 | 1 | 2010 |
| National Multiple Sclerosis Society | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Senopsys, LLC | For profit | 1 | 0 | 1 | 2018 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Miami | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Sherbrooke | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Zurich | Academic/Hospital | 1 | 1 | 1 | 2015 |
11 organizations
Page 1 / 1